RAPID, RELIABLE & ACCURATE

COVID-19

TESTING SOLUTIONS

COVID-19 DIAGNOSTICS ________

LATERAL FLOW ANTIGEN TESTING

Prognosis Biotech has developed the Rapid Test Ag 2019-nCov kits for the detection of SARS-CoV-2 antigen (nucleocapsid protein) in nasopharyngeal swab specimens.

This test is designed to rapidly identify infected individuals, enabling prompt clinical decisions and preventing potential virus outbreaks.

The Rapid Test Ag 2019-nCov does not require any special instrument or skill set and can be used in all types of premises where COVID-19 testing is required.

COVID-19 DIAGNOSTICS ________

LATERAL FLOW & ELISA ANTIBODY TESTING

Prognosis Biotech has developed the Rapid Test 2019-nCov Total Ig kits for the detection of SARS-CoV-2 Immunoglobulin antibodies in blood specimens.

This test is designed to detect a body’s immune response to SARS-CoV-2 (i.e., a past infection, not active infection) and comes in two different formats for application:

ELISA (Enzyme-linked immunosorbent assay) format made for testing laboratories. The following kits are available:

– Bio-Shield 2019-nCoV Total Immunoglobulins (IgA, IgG, IgM)

– Bio-Shield 2019-nCoV IgG

– Bio-Shield 2019-nCoV IgM

– Bio-Shield 2019-nCoV IgA

Rapid Lateral Flow format: an easy-to-use device with increased sensitivity that does not require any special instrument or skill set and can be used in all types of premises where COVID-19 testing is required.

COVID-19 DIAGNOSTICS ________

LATERAL FLOW ANTIGEN TESTING FOR SURFACES

The Rapid Surface Ag 2019-nCov is a rapid test for the detection of SARS-CoV-2 Nucleocapsid Protein Antigen (NP) in swabs of common surfaces, such as metal, plastic, glass, paper, and stainless steel. It is the first product for COVID-19 surface testing to utilize this innovative methodology.

The Rapid Surface Ag 2019-nCov is a valuable tool for several sectors enabling the companies to monitor and mitigate the spread of COVID-19 in their facilities and maintain a safe operating environment.